Tag: GCP compliance

Aligning ICH E6(R3) With Regional Regulations in the US, EU and UK

November 15, 2025November 15, 2025 digi

Aligning ICH E6(R3) With Regional Regulations in the US, EU and UK Aligning ICH E6(R3) With Regional Regulations in the US, EU and UK Introduction to ICH E6(R3) and Its Importance The International Council for Harmonisation (ICH) E6 guideline represents a fundamental component of Good Clinical Practice (GCP) in clinical research management. Updated most recently…

ICH E6(R3) Principles & Proportionality

Vendor and Partner Oversight Models That Reflect ICH E6(R3) Proportionality

November 15, 2025November 15, 2025 digi

Vendor and Partner Oversight Models That Reflect ICH E6(R3) Proportionality Vendor and Partner Oversight Models That Reflect ICH E6(R3) Proportionality The increasing complexity of clinical trials demands innovative approaches to vendor and partner oversight. As outlined in the ICH E6(R3) guidelines, these models must reflect a principle of proportionality, ensuring that oversight is commensurate with…

ICH E6(R3) Principles & Proportionality

Digital Enablement of Clinical QMS: Workflow, Automation and Analytics

November 15, 2025November 15, 2025 digi

Digital Enablement of Clinical QMS: Workflow, Automation and Analytics Digital Enablement of Clinical QMS: Workflow, Automation and Analytics In the rapidly evolving field of clinical trials, the integration of digital technologies into quality management systems (QMS) has become an essential focus for clinical operations, regulatory affairs, and medical affairs professionals. This article serves as a…

Quality Management System (QMS) Design

Documenting Attendance, Training and Competency at IMs and SIVs

November 15, 2025November 15, 2025 digi

Documenting Attendance, Training and Competency at IMs and SIVs Documenting Attendance, Training and Competency at IMs and SIVs Introduction to IMs and SIVs The initiation of clinical trials relies heavily on the effective coordination and management of various activities. One crucial aspect that contributes to this is the documentation of attendance, training, and competency at…

Investigator Meeting & Site Initiation Visit

Managing Protocol Changes Between Investigator Meeting and SIV

November 15, 2025November 15, 2025 digi

Managing Protocol Changes Between Investigator Meeting and Site Initiation Visit In the landscape of clinical trials, ensuring compliance with regulatory requirements is paramount. For professionals involved in clinical operations, regulatory affairs, and medical affairs, effective management of protocol changes between the Investigator Meeting (IM) and Site Initiation Visit (SIV) is critical. This guide presents a…

Investigator Meeting & Site Initiation Visit

ICH E6(R3) and Patient-Centricity: Rebalancing Burden and Benefit

November 15, 2025November 15, 2025 digi

ICH E6(R3) and Patient-Centricity: Rebalancing Burden and Benefit ICH E6(R3) and Patient-Centricity: Rebalancing Burden and Benefit The paradigm of clinical research has evolved significantly, particularly in the context of the increasing emphasis on patient-centric approaches. As global regulatory bodies such as the FDA, EMA, and MHRA advocate for integrating patient voices in clinical trials, adherence…

ICH E6(R3) Principles & Proportionality

Inspection Readiness in the Era of ICH E6(R3): New Expectations for Evidence

November 15, 2025November 15, 2025 digi

Inspection Readiness in the Era of ICH E6(R3): New Expectations for Evidence Inspection Readiness in the Era of ICH E6(R3): New Expectations for Evidence Introduction to Inspection Readiness and ICH E6(R3) The evolving landscape of clinical trials necessitates a framework that enhances compliance and ensures data integrity. The International Council for Harmonisation (ICH) E6(R3) guidelines…

ICH E6(R3) Principles & Proportionality

Integrating QMS, GCP and PV Requirements Across the Development Portfolio

November 15, 2025November 15, 2025 digi

Integrating QMS, GCP and PV Requirements Across the Development Portfolio Integrating QMS, GCP and PV Requirements Across the Development Portfolio The clinical trial landscape is increasingly complex due to the growing regulatory requirements and the high stakes involved in drug development. An effective Quality Management System (QMS) that integrates Good Clinical Practice (GCP) and Pharmacovigilance…

Quality Management System (QMS) Design

Using Investigator Meetings to Clarify Complex Endpoints and Assessments

November 15, 2025November 15, 2025 digi

Using Investigator Meetings to Clarify Complex Endpoints and Assessments Using Investigator Meetings to Clarify Complex Endpoints and Assessments Investigator meetings are critical components in the development of successful clinical trials, particularly for complex studies involving nuanced endpoints and assessments. These meetings serve as a platform for site management organizations, clinical research teams, and investigators to…

Investigator Meeting & Site Initiation Visit

Engagement Tactics to Turn Investigators Into Study Champions

November 15, 2025November 15, 2025 digi

Engagement Tactics to Turn Investigators Into Study Champions Engagement Tactics to Turn Investigators Into Study Champions In the ever-evolving landscape of clinical research, the role of investigators is paramount. Not only do they conduct the trials, but they also influence patient recruitment, retention, and overall study success. Proper engagement strategies can turn an ordinary investigator…

Investigator Meeting & Site Initiation Visit